magent
Deterministic published-formula arithmetic plus ICD-10-CM, RxNorm, and LOINC. Pay in USDC on Base via x402.
Tradingofflineeip155:8453Exactvia cdp
Hfa-icosHer2Cardio-oncologyTrastuzumabCalculator
Calls · 30d
1→ 0%
This endpoint's own trailing-30-day call count, as published by the upstream catalog and snapshotted daily. 7 snapshots so far.
$13.75
Verified settled volume
2,750 settlements proven x402 by their on-chain EIP-3009 marker.
$0.0050
Listed price
As published in the catalog. Always read the live 402 before paying.
1
Calls · 30d
Upstream's own call count for this endpoint, not ours.
1
Unique payers · 30d
Last called 2026-09-02 23:27Z
—
Upstream on-chain volume
Reported by the source catalog.
Paid to
0x836Be278f1739fB4308091cD1852F7971Bc19Ee2The wallet the 402 directs payment to. Its whole payment record — every payer, every chain — is on the merchant page.
Asset 0x833589fCD6eDb6E08f4c7C32D4f71b54bdA02913
Provider
The payTo wallet does not resolve to a registered ERC-8004 agent. That is not a verdict on the service — most of the catalog is unregistered.
Live 402 challenge
Captured by the enrichment pass, not read just now. Prices can change — always read the 402 the endpoint answers with.
{
"error": "PAYMENT-SIGNATURE header is required",
"accepts": [
{
"asset": "0x833589fCD6eDb6E08f4c7C32D4f71b54bdA02913",
"extra": {
"name": "USD Coin",
"version": "2",
"paymentFlow": "upfront",
"resourceUrl": "https://api.magentlab.com/api/calc/hfa_icos_her2",
"assetTransferMethod": "eip3009"
},
"payTo": "0x836Be278f1739fB4308091cD1852F7971Bc19Ee2",
"amount": "5000",
"scheme": "exact",
"network": "eip155:8453",
"maxTimeoutSeconds": 600
},
{
"asset": "0x833589fCD6eDb6E08f4c7C32D4f71b54bdA02913",
"extra": {
"name": "USD Coin",
"version": "2",
"withdrawDelay": 86400,
"receiverAuthorizer": "0x3721824a31197dcDD2984cF43b92B6cc8A87c0Fb",
"assetTransferMethod": "eip3009"
},
"payTo": "0x836Be278f1739fB4308091cD1852F7971Bc19Ee2",
"amount": "5000",
"scheme": "batch-settlement",
"network": "eip155:8453",
"maxTimeoutSeconds": 600
}
],
"resource": {
"url": "https://api.magentlab.com/api/calc/hfa_icos_her2",
"tags": [
"hfa-icos",
"her2",
"cardio-oncology",
"trastuzumab",
"calculator"
],
"mimeType": "application/json",
"description": "Lyon 2020 HFA-ICOS baseline cardiovascular risk before HER2-targeted therapy (trastuzumab and related agents). Very high, high, medium, or low from published factors plus Medium 1/2 points; expert-opinion cardiotoxicity guide <2% / 2-9% / 10-19% / >=20%. Concurrent anthracycline is High; sequential anthracycline before HER2 is Medium 1. Deterministic published classification with citation; not a treatment order. magent does not measure LVEF or biomarkers.",
"serviceName": "magent"
},
"extensions": {
"bazaar": {
"info": {
"input": {
"type": "http",
"method": "GET",
"queryParams": {
"ckd": false,
"obesity": false,
"diabetes": false,
"age_years": 50,
"arrhythmia": false,
"mi_or_cabg": false,
"elevated_bnp": false,
"hypertension": false,
"lvef_percent": 60,
"stable_angina": false,
"elevated_troponin": false,
"anthracycline_before_her2": false,
"prior_remote_anthracycline": false,
"current_or_significant_smoker": false,
"severe_valvular_heart_disease": false,
"heart_failure_or_cardiomyopathy": false,
"prior_trastuzumab_cardiotoxicity": false,
"concurrent_anthracycline_and_her2": false,
"prior_left_chest_or_mediastinal_rt": false
}
},
"output": {
"type": "json",
"example": {
"score": 0,
"formula": "hfa_icos_her2",
"citation": {
"id": "lyon-2020",
"doi": "10.1002/ejhf.1920",
"pmid": "32458582",
"title": "Baseline cardiovascular risk assessment in cancer patients scheduled to receive cardiotoxic cancer therapies: a position statement and new risk assessment tools from the Cardio-Oncology Study Group of the Heart Failure Association of the European Society of Cardiology in collaboration with the International Cardio-Oncology Society",
"source": "Eur J Heart Fail. 2020;22(11):1945-1960",
"authors": "Lyon AR, Dent S, Stanway S, et al."
},
"age_years": 50,
"max_score": 20,
"components": [
{
"factor": "heart_failure_or_cardiomyopathy",
"points": 0,
"present": false
},
{
"factor": "prior_trastuzumab_cardiotoxicity",
"points": 0,
"present": false
},
{
"factor": "mi_or_cabg",
"points": 0,
"present": false
},
{
"factor": "stable_angina",
"points": 0,
"present": false
},
{
"factor": "severe_valvular_heart_disease",
"points": 0,
"present": false
},
{
"value": 60,
"factor": "lvef_lt_50",
"points": 0,
"present": false
},
{
"value": 50,
"factor": "age_ge_80",
"points": 0,
"present": false
},
{
"factor": "concurrent_anthracycline_and_her2",
"points": 0,
"present": false
},
{
"value": 60,
"factor": "lvef_50_54",
"points": 0,
"present": false
},
{
"factor": "arrhythmia",
"points": 0,
"present": false
},
{
"factor": "elevated_troponin",
"points": 0,
"present": false
},
{
"factor": "elevated_bnp",
"points": 0,
"present": false
},
{
"value": 50,
"factor": "age_65_79",
"points": 0,
"present": false
},
{
"factor": "prior_remote_anthracycline",
"points": 0,
"present": false
},
{
"factor": "prior_left_chest_or_mediastinal_rt",
"points": 0,
"present": false
},
{
"factor": "hypertension",
"points": 0,
"present": false
},
{
"factor": "diabetes",
"points": 0,
"present": false
},
{
"factor": "ckd",
"points": 0,
"present": false
},
{
"factor": "anthracycline_before_her2",
"points": 0,
"present": false
},
{
"factor": "current_or_significant_smoker",
"points": 0,
"present": false
},
{
"factor": "obesity",
"points": 0,
"present": false
}
],
"disclaimer": "Not a medical device. Deterministic published-formula or published-code output for autonomous agents. A licensed clinician remains responsible for patient care and billing submissions.",
"risk_level": "low",
"high_present": false,
"lvef_percent": 60,
"medium_points": 0,
"very_high_present": false,
"formula_expression": "HFA-ICOS HER2 (Lyon 2020): very_high if heart_failure_or_cardiomyopathy or prior_trastuzumab_cardiotoxicity; else high if mi_or_cabg or stable_angina or severe_valvular_heart_disease or lvef_percent<50 or age_years>=80 or concurrent_anthracycline_and_her2 or medium_points>=5; else medium if medium_points 2-4; else low; medium_points = Medium 2 (2) + Medium 1 (1); Medium 2 = lvef 50-54, arrhythmia, elevated_troponin, elevated_bnp, age 65-79, prior_remote_anthracycline, prior_left_chest_or_mediastinal_rt; Medium 1 = hypertension, diabetes, ckd, anthracycline_before_her2 (if not concurrent), current_or_significant_smoker, obesity; cardiotoxicity_guide low <2%, medium 2-9%, high 10-19%, very_high >=20%",
"cardiotoxicity_guide": "<2%",
"anthracycline_before_her2": false,
"concurrent_anthracycline_and_her2": false
}
},
"iconUrl": "https://api.magentlab.com/favicon.ico"
},
"schema": {
"type": "object",
"$schema": "https://json-schema.org/draft/2020-12/schema",
"required": [
"input"
],
"properties": {
"input": {
"type": "object",
"required": [
"type",
"method"
],
"properties": {
"type": {
"type": "string",
"const": "http"
},
"method": {
"enum": [
"GET",
"HEAD",
"DELETE"
],
"type": "string"
},
"headers": {
"type": "object",
"additionalProperties": {
"type": "string"
}
},
"queryParams": {
"type": "object",
"required": [
"age_years",
"lvef_percent",
"heart_failure_or_cardiomyopathy",
"prior_trastuzumab_cardiotoxicity",
"mi_or_cabg",
"stable_angina",
"severe_valvular_heart_disease",
"concurrent_anthracycline_and_her2",
"arrhythmia",
"elevated_troponin",
"elevated_bnp",
"prior_remote_anthracycline",
"prior_left_chest_or_mediastinal_rt",
"hypertension",
"diabetes",
"ckd",
"anthracycline_before_her2",
"current_or_significant_smoker",
"obesity"
],
"properties": {
"ckd": {
"type": "boolean",
"description": "Chronic kidney disease as assigned by the caller (Lyon 2020 HER2 table Medium 1). true or false."
},
"obesity": {
"type": "boolean",
"description": "Obesity as assigned by the caller (Lyon 2020 HER2 table Medium 1). true or false. magent does not compute BMI."
},
"diabetes": {
"type": "boolean",
"description": "Diabetes mellitus as assigned by the caller (Lyon 2020 HER2 table Medium 1). true or false."
},
"age_years": {
"type": "integer",
"description": "Age in years (integer 18-100). Lyon 2020 exclusive bands: ≥80 is High; 65-79 is Medium 2 (2 points); younger than 65 does not score. Age 80 is High, not Medium 2."
},
"arrhythmia": {
"type": "boolean",
"description": "Atrial fibrillation, atrial flutter, VT, or VF as assigned by the caller (Lyon 2020 HER2 table Medium 2). true or false. magent does not interpret the ECG."
},
"mi_or_cabg": {
"type": "boolean",
"description": "Prior myocardial infarction or CABG as assigned by the caller (Lyon 2020 HER2 table High). true or false."
},
"elevated_bnp": {
"type": "boolean",
"description": "Elevated BNP or NT-proBNP as assigned by the caller (Lyon 2020 HER2 table Medium 2). true or false. magent does not assay natriuretic peptides."
},
"hypertension": {
"type": "boolean",
"description": "Hypertension as assigned by the caller (Lyon 2020 HER2 table Medium 1). true or false."
},
"lvef_percent": {
"type": "integer",
"description": "Left-ventricular ejection fraction percent (integer 10-80) as assigned by the caller. <50 is High; 50-54 is Medium 2 (2 points); ≥55 does not score. magent does not measure LVEF."
},
"stable_angina": {
"type": "boolean",
"description": "Stable angina as assigned by the caller (Lyon 2020 HER2 table High). true or false."
},
"elevated_troponin": {
"type": "boolean",
"description": "Elevated troponin as assigned by the caller (Lyon 2020 HER2 table Medium 2). true or false. magent does not assay troponin."
},
"anthracycline_before_her2": {
"type": "boolean",
"description": "Current regimen includes anthracycline before HER2-targeted therapy, sequential not concurrent (Lyon 2020 HER2 table Medium 1). true or false. Ignored for points when concurrent_anthracycline_and_her2 is true."
},
"prior_remote_anthracycline": {
"type": "boolean",
"description": "Prior remote anthracycline for a previous malignancy, not the current protocol (Lyon 2020 HER2 table footnote g; Medium 2). true or false."
},
"current_or_significant_smoker": {
"type": "boolean",
"description": "Current or significant smoking history as assigned by the caller (Lyon 2020 HER2 table Medium 1). true or false."
},
"severe_valvular_heart_disease": {
"type": "boolean",
"description": "Severe valvular heart disease as assigned by the caller (Lyon 2020 HER2 table High). true or false."
},
"heart_failure_or_cardiomyopathy": {
"type": "boolean",
"description": "Heart failure or cardiomyopathy as assigned by the caller (Lyon 2020 HER2 table Very high). true or false."
},
"prior_trastuzumab_cardiotoxicity": {
"type": "boolean",
"description": "Prior trastuzumab cardiotoxicity as assigned by the caller (Lyon 2020 HER2 table Very high). true or false. magent does not review prior exposure."
},
"concurrent_anthracycline_and_her2": {
"type": "boolean",
"description": "Anthracycline and trastuzumab delivered concurrently on the current protocol (Lyon 2020 HER2 table footnote f; High). true or false. When true, anthracycline_before_her2 does not add Medium 1 points."
},
"prior_left_chest_or_mediastinal_rt": {
"type": "boolean",
"description": "Prior left-chest or mediastinal radiotherapy as assigned by the caller (Lyon 2020 HER2 table Medium 2). true or false."
}
}
}
},
"additionalProperties": false
},
"output": {
"type": "object",
"required": [
"type"
],
"properties": {
"type": {
"type": "string"
},
"example": {
"type": "object"
}
}
}
}
}
}
},
"x402Version": 2
}Accepts
The payment requirements as published to the catalog. Read the live 402 before paying — a price here is a claim, not a quote.
0.005USDC≈ $0.005 USD
on Base · exact scheme
Pay 0.005 USDC on Base to 0x836B…19Ee2. The signed payment is good for 10 minutes.
- Paid to
- 0x836B…19Ee2
- USD Coin contract
- 0x8335…02913
- Payment window
- 10 minutes
- As published
- 5000 smallest units
The catalog’s raw entry
[
{
"asset": "0x833589fCD6eDb6E08f4c7C32D4f71b54bdA02913",
"extra": {
"name": "USD Coin",
"version": "2",
"paymentFlow": "upfront",
"resourceUrl": "https://api.magentlab.com/api/calc/hfa_icos_her2",
"assetTransferMethod": "eip3009"
},
"payTo": "0x836Be278f1739fB4308091cD1852F7971Bc19Ee2",
"amount": "5000",
"scheme": "exact",
"network": "eip155:8453",
"maxTimeoutSeconds": 600
}
]Extensions
{
"bazaar": {
"info": {
"input": {
"body": {
"items": [
{
"ckd": false,
"obesity": false,
"diabetes": false,
"age_years": 50,
"arrhythmia": false,
"mi_or_cabg": false,
"elevated_bnp": false,
"hypertension": false,
"lvef_percent": 60,
"stable_angina": false,
"elevated_troponin": false,
"anthracycline_before_her2": false,
"prior_remote_anthracycline": false,
"current_or_significant_smoker": false,
"severe_valvular_heart_disease": false,
"heart_failure_or_cardiomyopathy": false,
"prior_trastuzumab_cardiotoxicity": false,
"concurrent_anthracycline_and_her2": false,
"prior_left_chest_or_mediastinal_rt": false
},
{
"ckd": false,
"obesity": false,
"diabetes": false,
"age_years": 50,
"arrhythmia": false,
"mi_or_cabg": false,
"elevated_bnp": false,
"hypertension": false,
"lvef_percent": 60,
"stable_angina": false,
"elevated_troponin": false,
"anthracycline_before_her2": false,
"prior_remote_anthracycline": false,
"current_or_significant_smoker": false,
"severe_valvular_heart_disease": false,
"heart_failure_or_cardiomyopathy": false,
"prior_trastuzumab_cardiotoxicity": false,
"concurrent_anthracycline_and_her2": false,
"prior_left_chest_or_mediastinal_rt": false
}
]
},
"type": "http",
"method": "POST"
},
"output": {
"type": "json",
"example": {
"path": "/api/calc/hfa_icos_her2",
"count": 2,
"items": [
{
"score": 0,
"formula": "hfa_icos_her2",
"citation": {
"id": "lyon-2020",
"doi": "10.1002/ejhf.1920",
"pmid": "32458582",
"title": "Baseline cardiovascular risk assessment in cancer patients scheduled to receive cardiotoxic cancer therapies: a position statement and new risk assessment tools from the Cardio-Oncology Study Group of the Heart Failure Association of the European Society of Cardiology in collaboration with the International Cardio-Oncology Society",
"source": "Eur J Heart Fail. 2020;22(11):1945-1960",
"authors": "Lyon AR, Dent S, Stanway S, et al."
},
"age_years": 50,
"max_score": 20,
"components": [
{
"factor": "heart_failure_or_cardiomyopathy",
"points": 0,
"present": false
},
{
"factor": "prior_trastuzumab_cardiotoxicity",
"points": 0,
"present": false
},
{
"factor": "mi_or_cabg",
"points": 0,
"present": false
},
{
"factor": "stable_angina",
"points": 0,
"present": false
},
{
"factor": "severe_valvular_heart_disease",
"points": 0,
"present": false
},
{
"value": 60,
"factor": "lvef_lt_50",
"points": 0,
"present": false
},
{
"value": 50,
"factor": "age_ge_80",
"points": 0,
"present": false
},
{
"factor": "concurrent_anthracycline_and_her2",
"points": 0,
"present": false
},
{
"value": 60,
"factor": "lvef_50_54",
"points": 0,
"present": false
},
{
"factor": "arrhythmia",
"points": 0,
"present": false
},
{
"factor": "elevated_troponin",
"points": 0,
"present": false
},
{
"factor": "elevated_bnp",
"points": 0,
"present": false
},
{
"value": 50,
"factor": "age_65_79",
"points": 0,
"present": false
},
{
"factor": "prior_remote_anthracycline",
"points": 0,
"present": false
},
{
"factor": "prior_left_chest_or_mediastinal_rt",
"points": 0,
"present": false
},
{
"factor": "hypertension",
"points": 0,
"present": false
},
{
"factor": "diabetes",
"points": 0,
"present": false
},
{
"factor": "ckd",
"points": 0,
"present": false
},
{
"factor": "anthracycline_before_her2",
"points": 0,
"present": false
},
{
"factor": "current_or_significant_smoker",
"points": 0,
"present": false
},
{
"factor": "obesity",
"points": 0,
"present": false
}
],
"disclaimer": "Not a medical device. Deterministic published-formula or published-code output for autonomous agents. A licensed clinician remains responsible for patient care and billing submissions.",
"risk_level": "low",
"high_present": false,
"lvef_percent": 60,
"medium_points": 0,
"very_high_present": false,
"formula_expression": "HFA-ICOS HER2 (Lyon 2020): very_high if heart_failure_or_cardiomyopathy or prior_trastuzumab_cardiotoxicity; else high if mi_or_cabg or stable_angina or severe_valvular_heart_disease or lvef_percent<50 or age_years>=80 or concurrent_anthracycline_and_her2 or medium_points>=5; else medium if medium_points 2-4; else low; medium_points = Medium 2 (2) + Medium 1 (1); Medium 2 = lvef 50-54, arrhythmia, elevated_troponin, elevated_bnp, age 65-79, prior_remote_anthracycline, prior_left_chest_or_mediastinal_rt; Medium 1 = hypertension, diabetes, ckd, anthracycline_before_her2 (if not concurrent), current_or_significant_smoker, obesity; cardiotoxicity_guide low <2%, medium 2-9%, high 10-19%, very_high >=20%",
"cardiotoxicity_guide": "<2%",
"anthracycline_before_her2": false,
"concurrent_anthracycline_and_her2": false
},
{
"score": 0,
"formula": "hfa_icos_her2",
"citation": {
"id": "lyon-2020",
"doi": "10.1002/ejhf.1920",
"pmid": "32458582",
"title": "Baseline cardiovascular risk assessment in cancer patients scheduled to receive cardiotoxic cancer therapies: a position statement and new risk assessment tools from the Cardio-Oncology Study Group of the Heart Failure Association of the European Society of Cardiology in collaboration with the International Cardio-Oncology Society",
"source": "Eur J Heart Fail. 2020;22(11):1945-1960",
"authors": "Lyon AR, Dent S, Stanway S, et al."
},
"age_years": 50,
"max_score": 20,
"components": [
{
"factor": "heart_failure_or_cardiomyopathy",
"points": 0,
"present": false
},
{
"factor": "prior_trastuzumab_cardiotoxicity",
"points": 0,
"present": false
},
{
"factor": "mi_or_cabg",
"points": 0,
"present": false
},
{
"factor": "stable_angina",
"points": 0,
"present": false
},
{
"factor": "severe_valvular_heart_disease",
"points": 0,
"present": false
},
{
"value": 60,
"factor": "lvef_lt_50",
"points": 0,
"present": false
},
{
"value": 50,
"factor": "age_ge_80",
"points": 0,
"present": false
},
{
"factor": "concurrent_anthracycline_and_her2",
"points": 0,
"present": false
},
{
"value": 60,
"factor": "lvef_50_54",
"points": 0,
"present": false
},
{
"factor": "arrhythmia",
"points": 0,
"present": false
},
{
"factor": "elevated_troponin",
"points": 0,
"present": false
},
{
"factor": "elevated_bnp",
"points": 0,
"present": false
},
{
"value": 50,
"factor": "age_65_79",
"points": 0,
"present": false
},
{
"factor": "prior_remote_anthracycline",
"points": 0,
"present": false
},
{
"factor": "prior_left_chest_or_mediastinal_rt",
"points": 0,
"present": false
},
{
"factor": "hypertension",
"points": 0,
"present": false
},
{
"factor": "diabetes",
"points": 0,
"present": false
},
{
"factor": "ckd",
"points": 0,
"present": false
},
{
"factor": "anthracycline_before_her2",
"points": 0,
"present": false
},
{
"factor": "current_or_significant_smoker",
"points": 0,
"present": false
},
{
"factor": "obesity",
"points": 0,
"present": false
}
],
"disclaimer": "Not a medical device. Deterministic published-formula or published-code output for autonomous agents. A licensed clinician remains responsible for patient care and billing submissions.",
"risk_level": "low",
"high_present": false,
"lvef_percent": 60,
"medium_points": 0,
"very_high_present": false,
"formula_expression": "HFA-ICOS HER2 (Lyon 2020): very_high if heart_failure_or_cardiomyopathy or prior_trastuzumab_cardiotoxicity; else high if mi_or_cabg or stable_angina or severe_valvular_heart_disease or lvef_percent<50 or age_years>=80 or concurrent_anthracycline_and_her2 or medium_points>=5; else medium if medium_points 2-4; else low; medium_points = Medium 2 (2) + Medium 1 (1); Medium 2 = lvef 50-54, arrhythmia, elevated_troponin, elevated_bnp, age 65-79, prior_remote_anthracycline, prior_left_chest_or_mediastinal_rt; Medium 1 = hypertension, diabetes, ckd, anthracycline_before_her2 (if not concurrent), current_or_significant_smoker, obesity; cardiotoxicity_guide low <2%, medium 2-9%, high 10-19%, very_high >=20%",
"cardiotoxicity_guide": "<2%",
"anthracycline_before_her2": false,
"concurrent_anthracycline_and_her2": false
}
]
}
},
"iconUrl": "https://api.magentlab.com/favicon.ico"
},
"schema": {
"type": "object",
"$schema": "https://json-schema.org/draft/2020-12/schema",
"required": [
"input"
],
"properties": {
"input": {
"type": "object",
"required": [
"type",
"method"
],
"properties": {
"body": {
"type": "object",
"required": [
"items"
],
"properties": {
"items": {
"type": "array",
"items": {
"type": "object",
"required": [
"age_years",
"lvef_percent",
"heart_failure_or_cardiomyopathy",
"prior_trastuzumab_cardiotoxicity",
"mi_or_cabg",
"stable_angina",
"severe_valvular_heart_disease",
"concurrent_anthracycline_and_her2",
"arrhythmia",
"elevated_troponin",
"elevated_bnp",
"prior_remote_anthracycline",
"prior_left_chest_or_mediastinal_rt",
"hypertension",
"diabetes",
"ckd",
"anthracycline_before_her2",
"current_or_significant_smoker",
"obesity"
],
"properties": {
"ckd": {
"type": "boolean",
"description": "Chronic kidney disease as assigned by the caller (Lyon 2020 HER2 table Medium 1). true or false."
},
"obesity": {
"type": "boolean",
"description": "Obesity as assigned by the caller (Lyon 2020 HER2 table Medium 1). true or false. magent does not compute BMI."
},
"diabetes": {
"type": "boolean",
"description": "Diabetes mellitus as assigned by the caller (Lyon 2020 HER2 table Medium 1). true or false."
},
"age_years": {
"type": "integer",
"description": "Age in years (integer 18-100). Lyon 2020 exclusive bands: ≥80 is High; 65-79 is Medium 2 (2 points); younger than 65 does not score. Age 80 is High, not Medium 2."
},
"arrhythmia": {
"type": "boolean",
"description": "Atrial fibrillation, atrial flutter, VT, or VF as assigned by the caller (Lyon 2020 HER2 table Medium 2). true or false. magent does not interpret the ECG."
},
"mi_or_cabg": {
"type": "boolean",
"description": "Prior myocardial infarction or CABG as assigned by the caller (Lyon 2020 HER2 table High). true or false."
},
"elevated_bnp": {
"type": "boolean",
"description": "Elevated BNP or NT-proBNP as assigned by the caller (Lyon 2020 HER2 table Medium 2). true or false. magent does not assay natriuretic peptides."
},
"hypertension": {
"type": "boolean",
"description": "Hypertension as assigned by the caller (Lyon 2020 HER2 table Medium 1). true or false."
},
"lvef_percent": {
"type": "integer",
"description": "Left-ventricular ejection fraction percent (integer 10-80) as assigned by the caller. <50 is High; 50-54 is Medium 2 (2 points); ≥55 does not score. magent does not measure LVEF."
},
"stable_angina": {
"type": "boolean",
"description": "Stable angina as assigned by the caller (Lyon 2020 HER2 table High). true or false."
},
"elevated_troponin": {
"type": "boolean",
"description": "Elevated troponin as assigned by the caller (Lyon 2020 HER2 table Medium 2). true or false. magent does not assay troponin."
},
"anthracycline_before_her2": {
"type": "boolean",
"description": "Current regimen includes anthracycline before HER2-targeted therapy, sequential not concurrent (Lyon 2020 HER2 table Medium 1). true or false. Ignored for points when concurrent_anthracycline_and_her2 is true."
},
"prior_remote_anthracycline": {
"type": "boolean",
"description": "Prior remote anthracycline for a previous malignancy, not the current protocol (Lyon 2020 HER2 table footnote g; Medium 2). true or false."
},
"current_or_significant_smoker": {
"type": "boolean",
"description": "Current or significant smoking history as assigned by the caller (Lyon 2020 HER2 table Medium 1). true or false."
},
"severe_valvular_heart_disease": {
"type": "boolean",
"description": "Severe valvular heart disease as assigned by the caller (Lyon 2020 HER2 table High). true or false."
},
"heart_failure_or_cardiomyopathy": {
"type": "boolean",
"description": "Heart failure or cardiomyopathy as assigned by the caller (Lyon 2020 HER2 table Very high). true or false."
},
"prior_trastuzumab_cardiotoxicity": {
"type": "boolean",
"description": "Prior trastuzumab cardiotoxicity as assigned by the caller (Lyon 2020 HER2 table Very high). true or false. magent does not review prior exposure."
},
"concurrent_anthracycline_and_her2": {
"type": "boolean",
"description": "Anthracycline and trastuzumab delivered concurrently on the current protocol (Lyon 2020 HER2 table footnote f; High). true or false. When true, anthracycline_before_her2 does not add Medium 1 points."
},
"prior_left_chest_or_mediastinal_rt": {
"type": "boolean",
"description": "Prior left-chest or mediastinal radiotherapy as assigned by the caller (Lyon 2020 HER2 table Medium 2). true or false."
}
}
},
"maxItems": 25,
"minItems": 1
}
},
"additionalProperties": false
},
"type": {
"type": "string",
"const": "http"
},
"method": {
"type": "string",
"const": "POST"
},
"headers": {
"type": "object",
"additionalProperties": {
"type": "string"
}
}
},
"additionalProperties": false
},
"output": {
"type": "object",
"required": [
"type"
],
"properties": {
"type": {
"type": "string"
},
"example": {
"type": "object"
}
}
}
}
}
}
}Provenance
- Seen in the source catalog
- 2026-09-02 23:27Z
- Last indexed by Roundhouse
- 2026-09-07 06:20Z
- Last enriched (probe, favicon, geo)
- 2026-09-11 15:16Z
- x402 version
- 2
- Max timeout
- 600s
- Liveness probe
- HTTP 0
Hand this page to an agent
Copy the prompt and paste it into Claude, an MCP client or your own agent — it will vet this service and call it over the free read API. No key, no account.
GET api.roundhouseai.io/v0/endpoints
This endpoint's own trailing-30-day call count, as published by the upstream catalog and snapshotted daily. 7 snapshots so far. Verified volume counts only settlements with an on-chain EIP-3009 marker.
Show the promptHide the prompt
Using Roundhouse, look up the x402 service magent and tell me whether it is worth paying: what a call costs, whether the endpoint answered when last probed, and what its payment record actually shows. curl -s 'https://api.roundhouseai.io/v0/endpoints?q=magent' curl -s 'https://api.roundhouseai.io/v0/merchants/<the payTo wallet returned above>' Then call it: read the price from the live 402 at https://api.magentlab.com/api/calc/hfa_icos_her2, never from a cached figure, and pay with an x402 client. The /v0 API needs an API key (`authorization: Bearer rh_live_…`) on everything except /v0/unified* and /v0/endpoints. Mint a personal key for $0.01 at GET https://api.roundhouseai.io/v0/test/x402, or use an organization key from https://roundhouseai.io/dashboard/team. If you do not have Roundhouse tools or skills installed, read https://roundhouseai.io/skill.md first — it is the whole procedure.